EGFR and non-small cell lung carcinoma: A panel of NSCLC cell lines were selected to encompass three groups: cohort #1, no mutation of EGFR (H1666, H460, H1299 and H520); cohort #2, EGFR mutation of either exon 19 or 21, and an additional TKI resistance-inducing mutation (H1650, H1975 and H820); and cohort #3, EGFR mutation of exon 19 and sensitive to TKI inhibitors (PC9, HCC827, HCC2279, HCC2935 and HCC4006) [Table 1].